BR112021021092A2 - Composições e métodos úteis na promoção de produção de leite - Google Patents
Composições e métodos úteis na promoção de produção de leiteInfo
- Publication number
- BR112021021092A2 BR112021021092A2 BR112021021092A BR112021021092A BR112021021092A2 BR 112021021092 A2 BR112021021092 A2 BR 112021021092A2 BR 112021021092 A BR112021021092 A BR 112021021092A BR 112021021092 A BR112021021092 A BR 112021021092A BR 112021021092 A2 BR112021021092 A2 BR 112021021092A2
- Authority
- BR
- Brazil
- Prior art keywords
- notch4
- milk production
- agent
- compositions
- promoting milk
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 5
- 239000008267 milk Substances 0.000 title abstract 5
- 210000004080 milk Anatomy 0.000 title abstract 5
- 235000013336 milk Nutrition 0.000 title abstract 5
- 230000001737 promoting effect Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000001753 Notch4 Receptor Human genes 0.000 abstract 8
- 108010029741 Notch4 Receptor Proteins 0.000 abstract 8
- 101000650694 Homo sapiens Roundabout homolog 1 Proteins 0.000 abstract 4
- 101000650697 Homo sapiens Roundabout homolog 2 Proteins 0.000 abstract 4
- 102100027702 Roundabout homolog 1 Human genes 0.000 abstract 4
- 102100027739 Roundabout homolog 2 Human genes 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 108091030071 RNAI Proteins 0.000 abstract 2
- 230000009368 gene silencing by RNA Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
COMPOSIÇÕES E MÉTODOS ÚTEIS NA PROMOÇÃO DE PRODUÇÃO DE LEITE. Trata-se de métodos, agentes e composições para promover a produção de leite em um mamífero são fornecidos. Agentes úteis para promover a produção de leite podem incluir um agente que inibe a atividade de NOTCH4. O agente pode inibir a atividade de NOTCH4 ligando-se a ROBO2 e/ou ligando-se a NOTCH4. O agente pode inibir NOTCH4 competindo com ROBO1 pela ligação ao ROBO2, tornando ROBO1 disponível para inibir a atividade de NOTCH4. O agente pode ser um domínio extracelular ROBO1 solúvel ou um anticorpo anti-NOTCH4 que inibe a atividade NOTCH4. O agente pode ser um construto de RNAi que inibe a expressão de NOTCH4 ou um construto de RNAi que inibe a expressão de ROBO2. Também são fornecidos aqui mamíferos transgênicos geneticamente modificados para a expressão de um domínio extracelular ROBO1 solúvel; inibição da expressão de ROBO2; e/ou inibição da expressão de NOTCH4. Métodos para promover a produção de leite em tais mamíferos transgênicos por administração de um ou mais dos agentes divulgados no presente documento também são fornecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962837590P | 2019-04-23 | 2019-04-23 | |
PCT/US2020/029386 WO2020219592A1 (en) | 2019-04-23 | 2020-04-22 | Compositions and methods useful in promoting milk production |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021021092A8 BR112021021092A8 (pt) | 2021-12-14 |
BR112021021092A2 true BR112021021092A2 (pt) | 2023-02-28 |
Family
ID=72921278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021092A BR112021021092A2 (pt) | 2019-04-23 | 2020-04-22 | Composições e métodos úteis na promoção de produção de leite |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200339676A1 (pt) |
EP (1) | EP3959231A4 (pt) |
JP (1) | JP2022530033A (pt) |
CN (1) | CN114401982A (pt) |
AU (1) | AU2020262256A1 (pt) |
BR (1) | BR112021021092A2 (pt) |
CA (1) | CA3136663A1 (pt) |
WO (1) | WO2020219592A1 (pt) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
AU2003264177A1 (en) * | 2002-09-25 | 2004-04-19 | Garvan Institute Of Medical Research | Method for inducing mammary epithelial cell differentiation |
EP1744162B1 (en) * | 2004-03-31 | 2010-08-04 | Hiroyuki Aburatani | Cancer diagnosis and treatment using anti-robo1 antibody |
US8217000B2 (en) * | 2006-05-26 | 2012-07-10 | Cara Therapeutics, Inc. | Method for elevating prolactin in mammals |
AU2007279205B2 (en) * | 2006-07-28 | 2013-09-26 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
US20120192298A1 (en) * | 2009-07-24 | 2012-07-26 | Sigma Aldrich Co. Llc | Method for genome editing |
FR2958936A1 (fr) * | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
MX351313B (es) * | 2012-01-05 | 2017-10-10 | Boston Medical Ct Corp | Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón. |
GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
TWI691511B (zh) * | 2015-04-16 | 2020-04-21 | 日商衛材R&D企管股份有限公司 | 抗人類Notch4抗體 |
AU2018279705A1 (en) * | 2017-06-09 | 2019-11-14 | Boston Medical Center Corporation | Anti-ROBO2 antibodies, compositions, methods and uses thereof |
-
2020
- 2020-04-22 CA CA3136663A patent/CA3136663A1/en active Pending
- 2020-04-22 CN CN202080043614.1A patent/CN114401982A/zh active Pending
- 2020-04-22 EP EP20794298.8A patent/EP3959231A4/en active Pending
- 2020-04-22 AU AU2020262256A patent/AU2020262256A1/en active Pending
- 2020-04-22 JP JP2021562956A patent/JP2022530033A/ja active Pending
- 2020-04-22 US US16/855,883 patent/US20200339676A1/en active Pending
- 2020-04-22 WO PCT/US2020/029386 patent/WO2020219592A1/en unknown
- 2020-04-22 BR BR112021021092A patent/BR112021021092A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021021092A8 (pt) | 2021-12-14 |
CN114401982A (zh) | 2022-04-26 |
WO2020219592A1 (en) | 2020-10-29 |
AU2020262256A1 (en) | 2021-12-16 |
CA3136663A1 (en) | 2020-10-29 |
EP3959231A1 (en) | 2022-03-02 |
EP3959231A4 (en) | 2023-01-25 |
US20200339676A1 (en) | 2020-10-29 |
JP2022530033A (ja) | 2022-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Baker et al. | Distribution and Ca2+ signalling of fibroblast‐like (PDGFRα+) cells in the murine gastric fundus | |
Erpenbeck et al. | Inhibition of platelet GPIbα and promotion of melanoma metastasis | |
Neidhart et al. | Inhibition of spermidine/spermine N1‐acetyltransferase activity: a new therapeutic concept in rheumatoid arthritis | |
BR112019001247A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para produzir o anticorpo ou fragmento de ligação ao antígeno, composição, e, método de inibição da ativação do complemento da via alternativa em um mamífero. | |
BRPI0211953B8 (pt) | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro | |
UY33144A (es) | Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana | |
BR112016029226A2 (pt) | métodos e composições para o tratamento de úlceras | |
Unger-Torroledo et al. | Lethal toxin of Clostridium sordellii is associated with fatal equine atypical myopathy | |
BR112013031485A8 (pt) | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais | |
BR112022021690A2 (pt) | Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas | |
BR112019023820A2 (pt) | moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel | |
BR112016006649A2 (pt) | biscoito macio com glicose de liberação lenta | |
BR112018008839A8 (pt) | métodos e composições para o tratamento da amiloidose | |
Hempel et al. | Binding of Plasmodium falciparum to CD36 can be shielded by the glycocalyx | |
BR112021021176A2 (pt) | Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado | |
CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
BR112018074946A2 (pt) | produto lácteo fermentado com um teor reduzido de lactose | |
Ghoshal et al. | Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells | |
BR112021021092A2 (pt) | Composições e métodos úteis na promoção de produção de leite | |
BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
CL2017000578A1 (es) | Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia | |
BR112022012522A2 (pt) | Proteínas de ligação de tgf-beta-rii | |
BR112015020178A2 (pt) | composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico | |
Salmenkari et al. | Local corticosterone production and angiotensin-I converting enzyme shedding in a mouse model of intestinal inflammation | |
Packham et al. | In vivo evidence for platelet-induced physiological angiogenesis by a COX driven mechanism |